IL-6 inhibitors and abatacept showed encouraging results in preventing bone loss in RA, achieving better results on BMD than TNF inhibitors, especially at periarticular sites and in ACPA-positive patients [64,73,74]. The gene discussed is IL6; the disease is rheumatoid arthritis.